CoChat

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

Open access
Gupta, Sumit, Rau, Rachel E., Kairalla, John A., Rabin, Karen R., Wang, Cindy, Angiolillo, Anne L., Alexander, Sarah, Carroll, Andrew J., Conway, Susan, Gore, Lia, Kirsch, Ilan, Kubaney, Holly R., Li, Amanda M., McNeer, Jennifer L., Militano, Olga, Miller, Tamara P., Moyer, Yvonne, O’Brien, Maureen M., Okada, Maki, Reshmi, Shalini C., Shago, Mary, Wagner, Elizabeth, Winick, Naomi, Wood, Brent L., Haworth-Wright, Tara, Zaman, Faraz, Zugmaier, Gerhard, Zupanec, Sue, Devidas, Meenakshi, Hunger, Stephen P., Teachey, David T., Raetz, Elizabeth A., Loh, Mignon L. · 2025 · New England Journal of Medicine
Cited by 225

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes. METHODS: We conducted a phase 3 trial involving children with newly diagnosed standard-risk B-cell ALL who had an average or higher risk of relapse. Patients were randomly assigned to receive chemotherapy alone or chemotherapy plus two nonsequential 28-day cycles of blinatumomab. The primary end point was disease-free survival. RESULTS: The data and safety monitoring committee reviewed the results from the first interim efficacy analysis, which included 1440 patients who had undergone randomization (722 to chemotherapy alone and 718 to blinatumomab and chemotherapy) and recommended early termination of randomization. At a median follow-up of 2.5 years, the estimated 3-year disease-free survival (±SE) was 96.0±1.2% with blinatumomab and chemotherapy and 87.9±2.1% with chemotherapy alone (difference in restricted mean survival time, 72 days; 95% confidence interval, 36 to 108; P<0.001 by stratified log-rank test). The estimated 3-year disease-free survival among patients with an average relapse risk was 97.5±1.3% with blinatumomab and chemotherapy and 90.2±2.3% with chemotherapy alone; among those with a higher relapse risk, the corresponding values were 94.1±2.5% and 84.8±3.8%. Cytokine release syndrome, seizures, and sepsis of grade 3 or higher were rare during blinatumomab cycles, but the overall incidence of nonfatal sepsis and catheter-related infections was significantly higher among patients with an average relapse risk who had been assigned to receive blinatumomab and chemotherapy than among those assigned to receive chemotherapy alone. CONCLUSIONS: Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or higher risk of relapse significantly improved disease-free survival. (Funded by the National Institutes of Health and others; AALL1731 ClinicalTrials.gov number, NCT03914625.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2411680

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Metadata

Authors
Gupta, S., Rau, R. E., Kairalla, J. A., Rabin, K. R., Wang, C., Angiolillo, A. L., Alexander, S., Carroll, A. J., Conway, S., Gore, L., Kirsch, I., Kubaney, H. R., Li, A. M., McNeer, J. L., Militano, O., Miller, T. P., Moyer, Y., O’Brien, M. M., Okada, M., Reshmi, S. C., Shago, M., Wagner, E., Winick, N., Wood, B. L., Haworth-Wright, T., Zaman, F., Zugmaier, G., Zupanec, S., Devidas, M., Hunger, S. P., Teachey, D. T., Raetz, E. A., & Loh, M. L.
Venue
New England Journal of Medicine
Published
2025-02-27
Volume
392
Issue
9
Pages
875-891
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4405130232
Cited by
225
References
3
FWCI
85.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. https://app.cochat.ai/papers/10.1056/nejmoa2411680
The paper
Gupta, S., Rau, R. E., Kairalla, J. A., Rabin, K. R., Wang, C., Angiolillo, A. L., Alexander, S., Carroll, A. J., Conway, S., Gore, L., Kirsch, I., Kubaney, H. R., Li, A. M., McNeer, J. L., Militano, O., Miller, T. P., Moyer, Y., O’Brien, M. M., Okada, M., . . . Loh, M. L. (2025). Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2411680

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.